Company: LNAI
Filing Date: 2025-09-29
Form Type: 10-K
Source: 0001731122-25-001316
Chunk: 1165

Company: Lunai Bioworks Inc.
Filing Date: 2025-09-29
Form: 10-K
Item: Item 1
Chunk 1165
---
 planned pre-clinical studies could result in delays in our regulatory approval
efforts and significantly increase our costs to recover or reproduce the data. To the extent that any disruption or security breach were
to result in a loss of or damage to our data or applications, or inappropriate disclosure of confidential or proprietary information,
we could incur liability and further development of our product candidates could be delayed. Any disruption or loss of information technology
or telecommunications systems on which critical aspects of our operations depend could have an adverse effect on our business.

Intellectual
property litigation may lead to unfavorable publicity that harms our reputation.

During
the course of any intellectual property litigation, there could be public announcements of the initiation of the litigation as well as
results of hearings, rulings on motions and other interim proceedings in the litigation. Such announcements could harm our reputation,
the perceived value of our intellectual property or the potential market for our products, which could have a material adverse effect
on our business.

Renovaro
Cube’s and BioSymetrics’ success depends on our ability to develop and commercialize our technology without infringing, misappropriating,
or otherwise violating the intellectual property of third parties. Third parties may initiate legal proceedings alleging that Renovaro
Cube or BioSymetrics is infringing their intellectual property rights, and if they prevail, could block sales of Renovaro Cube’s
or BioSymetrics’ products and force us to make large damages and/or royalty payments, which could have a material adverse effect
on the success of our business.

Renovaro
Cube’s and BioSymetrics’ commercial success in part depends upon our ability, and the ability of our collaborators, to market,
sell and distribute our products and use our proprietary technologies without infringing, misappropriating or otherwise violating the
proprietary rights of third parties. There is considerable intellectual property litigation in the medical technology, biotechnology,
diagnostic and pharmaceutical industries. Renovaro Cube or BioSymetrics may become party to, or threatened with, future adversarial proceedings
or litigation regarding intellectual property rights with respect to its products, including interference proceedings before the United
Kingdom Intellectual Property Office, the European Patent Office, the United States
Patent and Trademark Office and similar bodies in other jurisdictions. Third parties may assert infringement claims against Renovaro Cube
or BioSymetrics based on existing patents or patents that may be issued in the future.

If Renovaro
Cube or BioSymetrics is found to infringe, misappropriate, or otherwise violate a third